Can lowering homocysteine levels reduce the incidence of stroke?

Journal of Clinical Pharmacy and Therapeutics

Volumn 24, Issue 5, 1999, Pages 331-338

  Sarkar, P K ^a   Lambert, L ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HUMAN; HYPERHOMOCYSTEINEMIA; REVIEW; RISK FACTOR; STROKE; THROMBOEMBOLISM; VEIN THROMBOSIS; VITAMIN SUPPLEMENTATION;

ANIMALS; ARTERIOSCLEROSIS; CEREBROVASCULAR ACCIDENT; HOMOCYSTEINE; HUMANS; INCIDENCE; RISK FACTORS;

EID: 0032710824     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1999.00244.x     Document Type: Review

References (57)

1. 1. De Vigneaud VE. (1952) Trail of Research in Sulfur Chemistry and Metabolism, and Related Fields. Ithaca, Cornell University Press.
2. 2. McCully KS. (1969) Vascular pathology of homocysteinaemia; implications for the pathogenesis of arteriosclerosis. American Journal of Pathology, 56, 111-128.
3. 3. Ueland PM, Refum H. (1989) Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease and drug therapy. Journal of Laboratory and Clinical Medicine, 114, 473-501.
4. 4. McCully KS. (1996) Homocysteine and vascular disease. Nat. Medicine, 2, 386-389.
5. 5. Ueland PM, Refsum H, Brattstrom L. (1992) Plasma homocysteine and cardiovascular disease. In: Francis KB Jr eds. Atherosclerosis Cardiovascular Disease, Haemostasis, and Endothelial Function. New York: Marcel Dekker, 183-236.
6. 6. Brattstrom LE. (1996) Vitnmins as homocysteine lowering agents. Journal of Nutrition, 126, 1276S-80S.
7. 7. Boers GM, Smals AGH, Trijbels FJM, et al. (1985) Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. New England Journal of Medicine, 313, 709-715.
8. 8. Selhub J, Jacques PF, Bostom AG, et al. (1995) Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. New England Journal of Medicine, 332, 286-291.
9. 9. Clarke R, Daly L, Robinson K, et al. (1991) Hyperhomocysteinaemia: an independent risk factor for vascular disease. New England Journal of Medicine, 324, 1149-1155.
10. 10. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. (1993) Carotid artery intimal-medial wall thickening and plasma homocysteine in asymptomatic adults: the Atherosclerosis risk in Communities study. Circulation, 87, 1107-1113.
11. 11. Pancharuniti N, Lewis CA, Sauberlich HE, et al. (1994) Plasma homocysteine, folate and Vitamin B12 concentrations and risk for early onset coronary artery disease. American Journal of Clinical Nutrition, 59, 940-948.
12. 12. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. (1995) Prospective study of serum total homocysteine concentrations and risk of stroke in middle-aged British men. Lancet, 346, 1395-1398.
13. 13. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. Journal of the American Medical Association, 274, 1049-1057.
14. 14. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer ML. (1997) Interrelation of hyperhomocysteinaemia, factor V Lelden, and risk of future venous thromboembolism. Circulation, 95, 1777-1782.
15. 15. Taylor LM Jr, DeFrang RD, Harris EJJ, Porter JM. (1991) The association of elevated plasma homocysteine with progression of symptomatic peripheral arterial disease. Journal of Vascular Surgery, 13, 128-136.
16. 16. Graham IM, Daly LE, Refsum HM, et al. (1997) Plasma homocysteine as a risk factor of vascular disease; the European Concerted Action Project. Journal of the American Medical Association, 277, 1775-1781.
17. 17. Verhoef P, Hennekens C, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. (1994) A prospective study of plasma homocysteine and risk of ischaemic stroke. Stroke, 25, 1924-1930.
18. 18. (1995) Disorders of transsulphuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D eds. The Metabolic and Molecular Bases of Inherited Disease, Vol 1, 7th edn, New York: McGraw-Hill, 1279-1327.
19. 19. Mudd SH, Skovby F, Levy HL, et al. (1985) The natural history of homocystineuria due to cystathionine beta-synthase deficiency. American Journal of Human Genetics, 37, 1-31.
20. 20. Mudd SH, Uhlendorf BW, Freeman JM, Finkelsteine JD, Shih VE. (1972) Homocysteinuria associated with decreased methyl enetetrahydrofolate reductase activity. Biochemical and Biophysical Reseach Communications, 46, 905-912.
21. 21. Frosst P, Blom HJ, Milos R, et al. (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Natural Genetics, 10, 111-113.
22. 22. Arruda VR, von Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF. (1997) The mutation Ala677-Val in the methylenetetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thrombosis and Haemostasis, 77(818-2), 1.
23. 23. Hiroyuki M, Hiroki K, et al. (1465) Methylene-tetrahydrofolate reductase gene polymorphism and ischaemic stroke in Japanese. Arteriosclerosis Thrombosis Vascular Biology, 18, 1465-1469.
24. 24. Brattstrom L, Israelsson B, Lindgarde F, Hultberg B. (1988) Higher total plasma homocysteine in Vitamin B12 deficiency than in heterozygosity for homocysteinuria due to cystathionine beta-synthase deficiency. Metabolism, 37, 175-178.
25. 25. Kang SS, Wong PWK, Norusis M. (1987) Homocysteinaernia due to folate deficiency. Metabolism, 36, 458-462.
26. 26. Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, Lindenbaum J. (1988) Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. Journal of Clinical Investigations, 81, 466-474.
27. 27. Wilcken DE, Gupta VJ. (1979) Sulphur containing amino acid in chronic renal failure with particular reference to homocysteine and cysteinehomocysteine mixed desulphide. European Journal of Clinical Investigations, 9, 301-307.
28. 28. Chauveau P, Chadefaux B, Coude M, et al. (1993) Hyperhomocysteinaemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney International Supplement, 41, S72-S77.
29. 29. Savage DG, Lindenbaum J, Stabler SP, Allen RH. (1994) Sensitivity of serum methylmalonic acid and total homocysteine determinants for diagnosing cobalamin and folate deficiencies. American Journal of Medicine 96, 239-246.
30. 30. Mayer EL, Jacobsen DW, Robinson K. (1996) Homocysteine and coronary atherosclerosis. Journal of the American College of Cardiology, 27, 517-527.
31. 31. Ubbink JB, van der Merwe A, Delport A, et al. (1996) The effect of a subnormal Vitamin B6 status of homocysteine metabolism. Journal of Clinical Investigations, 98, 177-184.
32. 32. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. (1993) Total homocysteine in plasma or serum: methods and clinical applications. Clinical Chemistry, 39, 1764-1779.
33. 33. Harker LA, Slichter SJ, Scott CR, Ross R. (1974) Homocysteinaemia, vascular injury and arterial thrombosis. New England Journal of Medicine, 291, 537-543.
34. 34. James TN. (1990) The spectrum of diseases of small coronary arteries and their physiologic consequences. Journal of the American College of Cardiology, 15, 763-774.
35. 35. Tsai X, Perrella MA, Yoshizumi M, et al. (1994) Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proceedings of the National Academy of Sciences of the USA, 91, 6369-6373.
36. 36. Wall RT, Harlan M, Harker LA, Striker GE. (1980) Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thrombosis Research, 18, 113-121.
37. 37. de Groot PG, Willems C, Boers GH, Gonsalves MD, van Aken WG, van Mourik JA. (1983) Endothelial cell dysfunction in homocysteinuria. European Journal of Clinical Investigations, 13, 405-410.
38. 38. Starkebaurn G, Harlan JM. (1986) Endothelial cell injury due to coppercatalysed hydrogen peroxide generation from homocysteine. Journal of Clinical Investigations, 77, 1370-1376.
39. 39. Misra HP. (1974) Generation of superoxide free radical during the autooxidation of thiols. Journal of Biological Chemistry, 249, 2151-2155.
40. 40. Rowley DA, Halliwell B. (1982) Superoxide-dependent formation of hydroxyl radicals in the presence of thiol compounds. FEBS Letters, 138, 33-36.
41. 41. Heinecke M. (1988) Superoxide-mediated oxidation of low density lipoprotein by thiols. In: Cerruti PA, Fridovich I, McCord JM eds. Oxyradicals in Molecular Biology and Pathology New York: Alan R Liss, 443-457.
42. 42. Loscalzo J. (1996) The oxidant stress of hyperhomocysteinaemia. Journal of Clinical Investigations, 98, 5-7.
43. 43. Welch GN, Upchurch GR Jr, Farivar RS, et. al. (1998) Homocysteine-induced nitric oxide production in vascular smooth muscle cells by NP-κB dependent transcriptional activation of NOs 2. Proceedings of the American Association of Physicians, 110, 22-31.
44. 44. Bellas RE, Lee JS, Sonenshein GE. (1995) Expression of a constitutive NF-kappa B-like activity is essential for proliferation of cultured bovine vascular smooth muscle cells. Journal of Clinical Investigations, 96, 2521-2527.
45. 45. Idem. (1994) Chemical pathology of homocysteine. II. Carcinogenesis and homocysteine thiolactone metabolism. Annals of Clinical Laboratory and Science, 24, 27-59.
46. 46. Idem. (1971) Homocysteine metabolism in scurvy, growth and arteriosclerosis. Nature, 231, 391-392.
47. 47. Morel DW, Hessler JR, Chisolm GM. (1983) Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. Journal of Lipid Research, 24, 1070-1076.
48. 48. Hughes H, Mathews B, Lenz ML, Guyton JR. (1994) Cytotoxicity of oxidized LDL to porcine aortic smooth muscle cells is associated with the oxysterols 7-ketocholesterol and 7-hydroxychole sterol. Arteriosclerosis Thrombosis, 14, 1175-1185.
49. 49. Heinecke JW, Kawamura M, Suzuki L, Chait A. (1993) Oxidation of low density lipoprotein by thiol: superoxide-dependent and independent mechanisms. Journal of Lipid Research, 34, 2051-2061.
50. 50. Parthasarathy S. (1987) Oxidation of low-density lipoprotein by thiol compounds lends to its recognition by the acetyl LDL receptor. Biochemica and Biophysica Acta, 917, 33740.
51. 51. Wald NJ, Watt HC, Law MR, et al. (1998) Homocysteine and ischaemic heart disease: results of a prospective study with implications regarding prevention. Archives of International Medicine, 158, 862-867.
52. 52. Ridker PM, Manson JE, Buring JE, Shili J, et al. (1999) Homocysteine and risk of cardiovascular disease among postmenopausal women. Journal of the American Medical Association, 281, 1817-1821.
53. 53. Brattstrom LE, Israelsson B, Jeppsson JO, Hultberg BL. (1988) Folic acid - an innocuous means to reduce plasma homocysteine. Scandinavian Journal of Clinical Laboratory and Investigations, 48, 215-221.
54. 54. Saltzman E, Mason JB, Jacques PF, et al. (1994) B vitamin supplementation lowers homocysteine levels in heart disease. Clinical Research, 42, 172A. (Abstract).
55. 55. Landgren F, Israelsson B, Lindgren A, et al. (1995) Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. Journal of Internal Medicine, 237, 3818.
56. 56. Solberg LA, Strong JP. (1983) Risk factors and atherosclerotic lesions, a review of autopsy studies. Atherosclerosis, 3, 187-198.
57. 57. Ubbink JB, van den Merwe A, Vermaak WM, Delport R. (1993) Homocysteinaemia and the response to Vitamin supplements. Clinical Investigations, 71, 993-998.